Semaglutide
Injection or Sublingual
Many people struggle to lose weight despite doing everything right. You may be eating better, staying active, and still feel stuck in the same cycle. Hunger stays high, cravings return, and weight comes back after progress. Over time, this can make consistent progress feel harder, not easier.
Semaglutide is part of a doctor-supervised program designed to help reduce that cycle by addressing how your body regulates appetite, not just your habits.
Provider-directed dose and schedule
Is this treatment available in my state?
Injection: Not available in the following states: Alaska, Mississippi, New Jersey.
Oral: Not available in the following states: Alabama, Alaska, Arkansas, Mississippi, New Jersey.
How It Works
Semaglutide works by acting on a pathway in the body that helps regulate hunger and fullness. It may help reduce how often you feel hungry and support feeling satisfied with smaller amounts of food. This program uses a structured dosing plan that is adjusted over time based on your response and tolerance. A licensed provider reviews your intake and determines if treatment is appropriate. If prescribed, medication is provided with clear instructions and ongoing support. This may help reduce how often you think about food and make eating feel more controlled.
Understanding Your Options
Both Semaglutide and Tirzepatide are used in structured, provider-reviewed programs designed to support appetite regulation.
Semaglutide works on a single pathway involved in hunger and fullness and is often selected by patients starting with GLP-1 treatment.
Tirzepatide works on multiple pathways related to appetite and may be chosen by those looking for a broader approach.
Both options follow a guided dosing plan and can be adjusted over time based on your response. Semaglutide is often selected as a starting point for patients new to GLP-1 treatment, while Tirzepatide may be considered for a broader pathway approach.
Why This Approach Works
Weight management is often tied to how the body regulates hunger, not just willpower. This approach supports those signals while replacing guesswork with a structured, supervised plan. With provider oversight and clear dosing, the process is more controlled and easier to follow. You are not left to figure this out on your own.
Who It May Be For
People looking for a structured medical approach
Adults struggling with ongoing hunger or cravings
Those who feel stuck despite diet and activity
Individuals who prefer guided, provider-led care
Those seeking support with consistency and routine
Support &
Ongoing Care
With RestartRX®, you are not managing this process on your own. A licensed provider reviews your plan, and support is available if adjustments are needed. You will receive clear guidance on dosing, use, and next steps.
Product Options
Typical Dosing Overview
Your provider determines your starting dose and any adjustments based on your history and response.
One price for every prescribed injectable dose within your selected medication and plan. Complete a short assessment before each refill. Treatment and refills require provider approval.
Sublingual Option
Absorbed under the tongue as a non-injection option.
Used as part of a daily routine based on your provider-reviewed plan.
Concentration Details
For injections, your provider selects the dose, concentration, and vial size for your prescribed plan.
The oral option uses Semaglutide sublingual drops in a 15 mL bottle. Your provider selects the appropriate 1 mg/mL, 2 mg/mL, 3 mg/mL, 4 mg/mL, or 5 mg/mL concentration.
Selection Guidance
Choose your preferred form. Your provider selects the dose and any adjustments. Injectable plans use 4-week (28-day) treatment cycles. Oral purchase options remain one-time purchase or Auto-Refill with 30-day supplies. Recurring plans follow the billing schedule shown at checkout.
Formulation Notes
These options are compounded formulations prepared by a licensed pharmacy for an individual patient when clinically appropriate.
Semaglutide may be provided as a subcutaneous injection or sublingual drops. Some injection options include glycine and vitamin B12 as part of the formulation.
The compounded options offered here are not FDA-approved as specific drug products. Sublingual semaglutide is not FDA-approved. Your provider will determine the appropriate formulation and dose based on your medical history and treatment plan.
Safety Summary
Semaglutide (Injection)
Common Side Effects
- Nausea
- Vomiting
- Diarrhea
- Constipation
- Stomach discomfort
- Injection-site irritation
Do Not Use If
You have a personal or family history of medullary thyroid cancer (MTC), Multiple Endocrine Neoplasia syndrome type 2 (MEN2), or a prior serious allergy to semaglutide or its ingredients.
Serious risks include pancreatitis, gallbladder disease, dehydration-related kidney injury, severe allergic reaction, and possible thyroid C-cell tumors. See full safety information.
This compounded formulation is not FDA-approved as a specific drug product. Treatment requires review by a licensed clinician. Not all patients will qualify. This information does not replace medical advice.
Full Medication Safety Information
Active Ingredient
Semaglutide
Common Side Effects
- Nausea
- Vomiting
- Diarrhea
- Constipation
- Stomach discomfort
- Injection-site irritation
Serious Risks
- Pancreatitis
- Gallbladder disease
- Kidney injury related to dehydration
- Severe allergic reaction
- Possible thyroid C-cell tumors
Who Should Not Use
- Personal or family history of MTC
- MEN2 syndrome
- Prior serious allergy to semaglutide or its ingredients
Important Warnings
Semaglutide slows stomach emptying and may affect anesthesia or sedation. Tell your clinician about all medications, pregnancy or plans for pregnancy, and upcoming procedures.
FDA Status
The compounded formulation offered here is not FDA-approved as a specific drug product.
Semaglutide (Sublingual)
Common Side Effects
- Nausea
- Vomiting
- Diarrhea
- Constipation
- Stomach discomfort
Do Not Use If
You have a personal or family history of medullary thyroid cancer (MTC), Multiple Endocrine Neoplasia syndrome type 2 (MEN2), or a prior serious allergy to semaglutide or its ingredients.
Serious risks include pancreatitis, gallbladder disease, dehydration-related kidney injury, severe allergic reaction, and possible thyroid C-cell tumors. See full safety information.
Sublingual semaglutide is compounded and is not FDA-approved as a specific drug product. Treatment requires review by a licensed clinician. Not all patients will qualify. This information does not replace medical advice.
Full Medication Safety Information
Active Ingredient
Semaglutide
Common Side Effects
- Nausea
- Vomiting
- Diarrhea
- Constipation
- Stomach discomfort
Serious Risks
- Pancreatitis
- Gallbladder disease
- Kidney injury related to dehydration
- Severe allergic reaction
- Possible thyroid C-cell tumors
Who Should Not Use
- Personal or family history of MTC
- MEN2 syndrome
- Prior serious allergy to semaglutide or its ingredients
Important Warnings
Semaglutide slows stomach emptying and may affect anesthesia or sedation. Tell your clinician about all medications, pregnancy or plans for pregnancy, and upcoming procedures.
FDA Status
Sublingual semaglutide is compounded and is not FDA-approved as a specific drug product.
Start with a simple RestartRX medical review to see if this program is appropriate for you.